← Peptide library
Peptide comparison
This page compares BPC-157 and TB-500, two research peptides, and collects reconstitution and dosing-reference data reported for each. It is provided strictly for informational and harm-reduction purposes and is not medical advice. Neither compound is FDA-approved, and the entries below summarize regulatory status, available evidence, and the limited dosing references on record rather than recommending any use.
BPC-157
TB-500
Not FDA-approved; FDA reports limited safety information
Not FDA-approved; FDA lists the TB-500 fragment as a potential significant compounding safety risk
Extremely limited human data
No identified human exposure data for TB-500 fragment
No established injectable treatment route
No established human route
No established regimen
No established regimen
No established range
No established range
BPC-157 vs TB-500: at a glance
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Regulatory status | Not FDA-approved; FDA reports limited safety information | Not FDA-approved; FDA lists the TB-500 fragment as a potential significant compounding safety risk |
| Route | No established injectable treatment route | No established human route |
| Dosing frequency | No established regimen | No established regimen |
| Published range | No established range | No established range |
| Evidence basis | Extremely limited human data | No identified human exposure data for TB-500 fragment |
| What the source describes | A 2-person IV safety pilot used 10 mg then 20 mg; this does not establish an effective or SC dose | No clinically validated human dose for the TB-500 (LKKTETQ) fragment |
| Formulation | No default dose. Enter a value only from an approved research protocol or licensed prescriber/pharmacy instructions. | No default dose. Do not substitute full-length thymosin beta-4 study doses. |
Every value is quoted from each compound's own labeling or published trial, listed in the sources below. A published range describes what has been studied or labeled - it is not a recommendation, and this page does not advise choosing one compound over the other. There is no valid dose conversion between two different compounds.
What is not established
| Compound | Established dose range | Stated limitation |
|---|---|---|
| BPC-157 | None established | n=2 IV safety observation is not efficacy evidence and should not be extrapolated to subcutaneous self-use. |
| TB-500 | None established | FDA states it has not identified human exposure data for the TB-500 fragment and lacks safety information. |
Sources
| Compound | Primary source | Checked |
|---|---|---|
| BPC-157 | U.S. Food & Drug Administration - fda.gov | 2026-06-24 |
| TB-500 | U.S. Food & Drug Administration - fda.gov | 2026-06-24 |
INTERACTIVE
Plan the BPC-157 + TB-500 co-draw
Reconstitute each peptide in its own vial, then plan the same-syringe co-draw — the tool works out the concentration and U-100 units to draw for each. Both are set below; edit the vial size, water, and dose to match your own. Arithmetic only — not medical advice.
BPC-157 + TB-500 co-draw calculator X
Reconstitute each vial, then plan the same-syringe co-draw and read U-100 units for each.
Arithmetic checks out. Confirm clinically, against the label, and against the actual vial before any use.
Independent check - dose mg / concentration mg/mL = volume. U-100 units = mL x 100.
Same-syringe co-draw. Reconstitute each peptide in its own vial, then draw them into one syringe.
- Reconstitute each peptide in its own vial — never add water to multiple peptides in one vial.
- Only co-draw peptides with the same diluent (e.g. both bacteriostatic water) and compatible pH.
- Draw and inject fresh — do not pre-mix and store; mixture stability is not established.
- No blended stack is clinically validated. Verify each component and confirm with a clinician.
Key differences
Neither peptide is FDA-approved: the FDA reports limited safety information for BPC-157, while it lists the TB-500 (LKKTETQ) fragment as a potential significant compounding safety risk. The evidence tiers differ in degree but are both minimal, with BPC-157 having extremely limited human data and the TB-500 (LKKTETQ) fragment having no identified human exposure data. This summary reflects only the regulatory status and evidence tier on record for each compound and does not establish, compare, or recommend any use, route, or dose.
Reference comparison only. Not medical advice; verify with a clinician, product label, pharmacist, or approved research protocol.
Frequently asked questions
How are BPC-157 and TB-500 administered?
Neither has an established human treatment route or regimen. Both are research peptides that are not FDA-approved, and the FDA has flagged safety concerns — including listing the TB-500 fragment as a potential significant compounding safety risk. The table above summarizes this.
What dose range does this comparison reference?
Neither compound has an established dose range, so none is quoted. The calculator can still perform the arithmetic for whatever inputs you enter, but it does not imply any figure is a recommended dose.
Can I calculate reconstitution for both here?
Yes — the buttons above open each calculator to convert vial strength and bacteriostatic water into concentration (mg/mL), draw volume and U-100 syringe units. It is arithmetic only.
Does this page recommend either peptide?
No. It is a neutral reference that reflects the limited information available, and it does not assess safety, efficacy, or suitability. Consult a qualified professional and review the FDA’s safety statements.